CA2152256A1 - Vaccines against varicella-zoster virus (vzv) - Google Patents
Vaccines against varicella-zoster virus (vzv)Info
- Publication number
- CA2152256A1 CA2152256A1 CA002152256A CA2152256A CA2152256A1 CA 2152256 A1 CA2152256 A1 CA 2152256A1 CA 002152256 A CA002152256 A CA 002152256A CA 2152256 A CA2152256 A CA 2152256A CA 2152256 A1 CA2152256 A1 CA 2152256A1
- Authority
- CA
- Canada
- Prior art keywords
- vzv
- protein
- iep
- dna
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000701085 Human alphaherpesvirus 3 Species 0.000 title claims abstract description 71
- 229960005486 vaccine Drugs 0.000 title claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 65
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 60
- 239000013598 vector Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 7
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 7
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 7
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 230000006870 function Effects 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000356 contaminant Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 101000999689 Saimiriine herpesvirus 2 (strain 11) Transcriptional regulator ICP22 homolog Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 49
- 108020004414 DNA Proteins 0.000 description 41
- 239000013612 plasmid Substances 0.000 description 17
- 241000700605 Viruses Species 0.000 description 15
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 14
- 208000007514 Herpes zoster Diseases 0.000 description 11
- 239000012634 fragment Substances 0.000 description 8
- 241000701447 unidentified baculovirus Species 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 101100440639 Drosophila melanogaster Cont gene Proteins 0.000 description 4
- 241000714474 Rous sarcoma virus Species 0.000 description 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 4
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 229960000187 tissue plasminogen activator Drugs 0.000 description 4
- 101710182846 Polyhedrin Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000007420 reactivation Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000002788 anti-peptide Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 230000002480 immunoprotective effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 241001501536 Alethe Species 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 101100428614 Caenorhabditis elegans epg-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 101000626907 Chlamydomonas reinhardtii Uncharacterized 7.3 kDa protein in petA 5'region Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101000792437 Guillardia theta Uncharacterized 7.8 kDa protein Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710179282 Major DNA-binding protein Proteins 0.000 description 1
- 101710176004 Major viral transcription factor ICP4 homolog Proteins 0.000 description 1
- 101000747949 Marchantia polymorpha Uncharacterized mitochondrial protein ymf32 Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101000962056 Mytilus edulis Major extrapallial fluid protein Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 101710197985 Probable protein Rev Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- -1 Quil A Chemical class 0.000 description 1
- 241000282941 Rangifer tarandus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000004333 gold (food color) Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000010322 reactivation of latent virus Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929226768A GB9226768D0 (en) | 1992-12-23 | 1992-12-23 | Vaccines |
| GB9226768.1 | 1992-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2152256A1 true CA2152256A1 (en) | 1994-07-07 |
Family
ID=10727070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002152256A Abandoned CA2152256A1 (en) | 1992-12-23 | 1993-12-17 | Vaccines against varicella-zoster virus (vzv) |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0675957A1 (de) |
| JP (1) | JPH08504592A (de) |
| KR (1) | KR950704494A (de) |
| CN (1) | CN1095106A (de) |
| AU (1) | AU672870B2 (de) |
| CA (1) | CA2152256A1 (de) |
| GB (1) | GB9226768D0 (de) |
| MX (1) | MX9307998A (de) |
| NZ (1) | NZ259362A (de) |
| WO (1) | WO1994014962A1 (de) |
| ZA (1) | ZA939564B (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9901254D0 (en) * | 1999-01-20 | 1999-03-10 | Smithkline Beecham Biolog | Vaccines |
| CN110343722A (zh) * | 2019-07-03 | 2019-10-18 | 上海大学 | 一种重组表达水痘-带状疱疹病毒v-Oka株截短型糖蛋白E的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2071770T3 (es) * | 1989-06-27 | 1995-07-01 | Smithkline Beecham Biolog | Nuevos compuestos. |
| JP3026029B2 (ja) * | 1991-04-26 | 2000-03-27 | 財団法人阪大微生物病研究会 | 組換え水痘ウイルスとその作製法 |
-
1992
- 1992-12-23 GB GB929226768A patent/GB9226768D0/en active Pending
-
1993
- 1993-12-15 MX MX9307998A patent/MX9307998A/es unknown
- 1993-12-17 CA CA002152256A patent/CA2152256A1/en not_active Abandoned
- 1993-12-17 NZ NZ259362A patent/NZ259362A/en not_active IP Right Cessation
- 1993-12-17 EP EP94903844A patent/EP0675957A1/de not_active Withdrawn
- 1993-12-17 JP JP6514805A patent/JPH08504592A/ja active Pending
- 1993-12-17 AU AU58144/94A patent/AU672870B2/en not_active Expired
- 1993-12-17 KR KR1019950702600A patent/KR950704494A/ko not_active Application Discontinuation
- 1993-12-17 WO PCT/EP1993/003626 patent/WO1994014962A1/en not_active Application Discontinuation
- 1993-12-21 ZA ZA939564A patent/ZA939564B/xx unknown
- 1993-12-22 CN CN93119996A patent/CN1095106A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1095106A (zh) | 1994-11-16 |
| AU672870B2 (en) | 1996-10-17 |
| MX9307998A (es) | 1994-08-31 |
| ZA939564B (en) | 1994-08-15 |
| NZ259362A (en) | 1996-10-28 |
| EP0675957A1 (de) | 1995-10-11 |
| JPH08504592A (ja) | 1996-05-21 |
| KR950704494A (ko) | 1995-11-20 |
| WO1994014962A1 (en) | 1994-07-07 |
| AU5814494A (en) | 1994-07-19 |
| GB9226768D0 (en) | 1993-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0166585B1 (ko) | 앵커-결여 vzv 당단백질, 이를 제조하는 방법 및 이의 면역보호적 용도 | |
| JP3958360B2 (ja) | 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法 | |
| CA1341181C (en) | Vaccines based on membrane bound proteins and process for making them | |
| CA1320163C (en) | Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus | |
| US5714152A (en) | Herpes simplex virus VP16 vaccines | |
| US6485728B2 (en) | Formalin-Inactivated human papillomavirus L1 protein vaccine | |
| EP0272858A2 (de) | Rekombinante HIV-Hüllen-Proteine, hergestellt in Insektenzellen | |
| JP2002503251A (ja) | 単純ヘルペスウイルスｖｐ２２ワクチンおよび使用の方法 | |
| WO1996011273A1 (en) | Papillomavirus vaccine | |
| US7264817B1 (en) | Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it | |
| EP0769056B1 (de) | UNGESPLEISSTE VARIANTEN DES gp350/220 | |
| CA2152256A1 (en) | Vaccines against varicella-zoster virus (vzv) | |
| EP1546191A2 (de) | Dna-impfstoff kodierend für mindestens zwei frühe nichtstrukturproteine des papillomaviruses | |
| JPH05252965A (ja) | ＨＳＶ ｇＤ２バキユロウイルスの発現系 | |
| JP2001524821A (ja) | Ｅ型肝炎のパキスタン株組換えタンパク質および診断法およびワクチンにおけるそれらの使用 | |
| EP0770131A1 (de) | Immunodominante polypeptiden | |
| CA1341291C (en) | Vaccines based on membrane bound proteins and process for making them | |
| KR20000029687A (ko) | 면역치료제로서유용한폴리펩티드및폴리펩티드의제조방법 | |
| AU5013099A (en) | Papillomavirus vaccine | |
| AU4889102A (en) | Papillomavirus vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |